0001140361-23-007485.txt : 20230216
0001140361-23-007485.hdr.sgml : 20230216
20230216164543
ACCESSION NUMBER: 0001140361-23-007485
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230214
FILED AS OF DATE: 20230216
DATE AS OF CHANGE: 20230216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Militello John
CENTRAL INDEX KEY: 0001662170
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 23639088
MAIL ADDRESS:
STREET 1: C/O IMMUNE PHARMACEUTICALS INC.
STREET 2: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
X0306
4
2023-02-14
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001662170
Militello John
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
See Remarks
Stock Option (Right to Buy)
20.04
2023-02-14
4
A
0
49798
0
A
2033-02-13
Common Stock
49798
49798
D
Restricted Stock Units
2023-02-14
4
A
0
16616
0
A
Common Stock
16616
16616
D
This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
VP, Principal Accounting Officer and Interim Principal Financial Officer
/s/ Martin Wilson, as attorney-in-fact for John Militello
2023-02-16